Exelgen

Exelgen is a South Korean biotechnology company specializing in the development of next-generation gene and cell therapies using its proprietary non-viral delivery platform, Exo-GT. The Exo-GT platform leverages engineered exosomes to deliver therapeutic payloads, such as mRNA and DNA, specifically to target tissues while minimizing immunogenicity and overcoming the cargo size limitations of traditional viral vectors. The company's pipeline focuses on high-need areas including oncology, specifically glioblastoma and pancreatic cancer, as well as rare genetic disorders like Duchenne Muscular Dystrophy and Cystic Fibrosis. By utilizing the natural properties of exosomes for targeted delivery, Exelgen aims to provide safer and more effective genetic medicines for patients with limited treatment options. The company is currently advancing its lead candidates through preclinical development and seeking strategic partnerships for clinical expansion.